Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Atara Biotherapeutics Inc

ATRA
Current price
0.65 USD +0.0017 USD (+0.26%)
Last closed 0.66 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 66 422 568 USD
Yield for 12 month -86.07 %
Week
Month
Year
ATRA
21.11.2021 - 28.11.2021

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California. Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080

Analytics

WallStreet Target Price

3.94 USD

P/E ratio

Dividend Yield

Current Year

+63 573 000 USD

Last Year

+20 340 000 USD

Current Quarter

+2 138 000 USD

Last Quarter

+957 000 USD

Current Year

+63 573 000 USD

Last Year

+20 340 000 USD

Current Quarter

-477 000 USD

Last Quarter

-1 938 000 USD

Key Figures ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -280 784 992 USD
Operating Margin TTM -3255.94 %
PE Ratio
Return On Assets TTM -64.09 %
PEG Ratio
Return On Equity TTM -425.97 %
Wall Street Target Price 3.94 USD
Revenue TTM 4 542 000 USD
Book Value -0.48 USD
Revenue Per Share TTM 0.043 USD
Dividend Share
Quarterly Revenue Growth YOY -52.1 %
Dividend Yield
Gross Profit TTM 63 573 000 USD
Earnings Share -2.78 USD
Diluted Eps TTM -2.78 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ATRA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.3103
Price Sales TTM 4.5385
Enterprise Value EBITDA -0.5619
Price Book MRQ 1.9674

Financials ATRA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ATRA

For 52 weeks

0.2 USD 5.64 USD
50 Day MA 1.24 USD
Shares Short Prior Month 12 270 579
200 Day MA 2.12 USD
Short Ratio 10.73
Shares Short 12 486 213
Short Percent 12.56 %